SPRED2: A Potential Drug Target and Biomarker (G200734)

Target Name: SPRED2

NCBI ID: G200734

SPRED2: A Potential Drug Target and Biomarker

SPRED2, or SPRED2 variant 2, is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of cell proliferation and has been linked to a number of diseases, including cancer. In recent years, researchers have been investigating the potential drug targets of SPRED2 and have identified several potential biomarkers that may be associated with its dysfunction.

The SPRED2 gene is located on chromosome 6p and encodes a protein that is composed of 111 amino acid residues. SPRED2 is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract, and has been shown to play a role in the development and progression of several diseases, including cancer.

One of the key functions of SPRED2 is its role as a regulator of cell proliferation. SPRED2 has been shown to promote the growth and proliferation of various cell types, including cancer cells. This function is likely important for the development and progression of cancer, as it allows cells to grow and divide without control, leading to the formation of tumors.

In addition to its role in cell proliferation, SPRED2 has also been shown to play a role in cell survival. SPRED2 has been shown to protect cells from programmed cell death, known as apoptosis, which is a natural mechanism that helps cells remove themselves from the body when they are no longer needed. This function may be important for the development and maintenance of tissues and organs, as it helps ensure that they remain functional and healthy.

The potential drug targets of SPRED2 are many, and research into these targets is ongoing. One of the most promising targets is SPRED2's role as a regulator of cell proliferation. Researchers are interested in investigating the effects of drugs that specifically target SPRED2 on cell proliferation, as this may be a useful approach for the development of new treatments for cancer.

Another potential drug target for SPRED2 is its role as a regulator of cell survival. Researchers are interested in investigating the effects of drugs that specifically target SPRED2 on cell survival, as this may be a useful approach for the development of new treatments for diseases that are characterized by the loss of cells or tissues.

In addition to its potential drug targets, SPRED2 is also of interest as a biomarker for several diseases. SPRED2 has been shown to be expressed in a variety of tissues and cells, including cancer cells, and has been used as a biomarker for cancer diagnosis and treatment. In addition, SPRED2 has been shown to be involved in the development and progression of several other diseases, including neurodegenerative disorders and autoimmune diseases.

Research into SPRED2 and its potential drug targets is ongoing, and there is a lot of interest in this area. The identification of new drug targets and biomarkers for SPRED2 may lead to new and effective treatments for a variety of diseases.

Protein Name: Sprouty Related EVH1 Domain Containing 2

Functions: Negatively regulates Ras signaling pathways and downstream activation of MAP kinases (PubMed:15683364, PubMed:34626534). Recruits and translocates NF1 to the cell membrane, thereby enabling NF1-dependent hydrolysis of active GTP-bound Ras to inactive GDP-bound Ras (PubMed:34626534). Inhibits fibroblast growth factor (FGF)-induced retinal lens fiber differentiation, probably by inhibiting FGF-mediated phosphorylation of ERK1/2 (By similarity). Inhibits TGFB-induced epithelial-to-mesenchymal transition in lens epithelial cells (By similarity)

More Common Targets